ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1941 • ACR Convergence 2021

    The Risk of Venous Thromboembolic Events in Patients with RA Aged ≥ 50 Years with ≥ 1 Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors

    Christina Charles-Schoeman1, Roy Fleischmann2, Eduardo Mysler3, Maria Greenwald4, Cunshan Wang5, All-shine Chen5, Carol A Connell5, John C Woolcott6, Sujatha Menon5, Yan Chen7, Kristen Lee7 and Zoltan Szekanecz8, 1Department of Medicine, University of California, Los Angeles, Los Angeles, CA, 2Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 3Organización Médica de Investigación, Buenos Aires, Argentina, 4Desert Medical Advances, Palm Desert, CA, 5Pfizer Inc, Groton, CT, 6Pfizer Inc, Collegeville, PA, 7Pfizer Inc, New York, NY, 8Division of Rheumatology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary

    Background/Purpose: ORAL Surveillance (NCT02092467) was a randomized, open-label, non-inferiority, Phase 3b/4 study that assessed the relative risk of major adverse cardiovascular (CV) events (MACE) and…
  • Abstract Number: 1946 • ACR Convergence 2021

    Therapeutic Drug Monitoring Compared to Standard Infliximab Therapy in Patients with Immune-mediated Inflammatory Diseases: A Randomized Controlled Trial

    Silje Watterdal Syversen1, Guro Goll1, Kristin Jørgensen2, Marthe Brun1, Øystein Sandanger3, Kristin Hammersbøen2, Joseph Sexton1, Inge Olsen3, Johanna Gehin4, David Warren3, Rolf Anton Klaasen3, Trude Bruun5, Maud Kristine Ljoså6, Anne Haugen7, Rune Njålla8, Brigitte Michelsen9, Camilla Zettel10, Yngvill Bragenes11, Svanaug Skorpe12, Eldri Strand13, Pawel Mielnik14, Cato Mørk15, Tore Kvien1, Jørgen Jahnsen2, Nils Bolstad16 and Espen Haavardsholm1, 1Diakonhjemmet Hospital, Oslo, Norway, 2Akershus University Hospital, Lørenskog, Norway, 3Oslo University Hospital, Oslo, Norway, 4Oslo University Hospital, Lillehammer, Nepal, 5The University Hospital of North Norway, Tromsø, Norway, 6Dept. of Rheumatology, Ålesund Hospital, Ålesund, Norway, 7Østfold Hospital Trust, Moss, Norway, 8Nordland Hospital Trust, Bodø, Bodø, Norway, 9Hospital of Southern Norway Trust, Kristiansand, Norway, 10Betanien Hospital, Skien, Norway, 11Vestre Viken Hospital Trust, Drammen, Norway, 12Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway, 13Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, 14Førde Hospital Trust, Førde, Norway, 15Akershus Dermatology Center, Lørenskog, Norway, 16Oslo University Hospital, Radiumhospitalet, Oslo, Norway

    Background/Purpose: Proactive therapeutic drug monitoring (TDM), a treatment strategy based on scheduled assessments of serum drug levels, has been proposed to optimize efficacy and safety…
  • Abstract Number: 1945 • ACR Convergence 2021

    Efficacy of Upadacitinib on Psoriatic Arthritis with Axial Involvement Defined by Investigator Assessment and PRO-Based Criteria: Results from Two Phase 3 Studies

    Xenofon Baraliakos1, Roberto Ranza2, Andrew Ostor3, Francesco Ciccia4, Laura Coates5, Simona Rednic6, Jessica Walsh7, Tianming Gao8, Apinya Lertratanakul8, In-Ho Song8, Fabiana Ganz8, Kevin Douglas8 and Atul Deodhar9, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, 2Hospital de Clinicas, Universidade Federal de Uberlândia, Uberlandia, MG, Brazil, 3Monash University, Cabrini Hospital, and Emertius Research, Malvern, Australia, 4University of Campania Luigi Vanvitelli, Napoli, Italy, 5Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 6Emergency Clinical County Hospital, Rheumatology and Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania, 7Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, 8AbbVie Inc., North Chicago, IL, 9Oregon Health & Science University, Portland, OR

    Background/Purpose: Patients with PsA and axial involvement have higher disease activity and greater reductions in quality of life;1 however, there are no accepted criteria for…
  • Abstract Number: PP01 • ACR Convergence 2021

    Unicycling for a Cure: My UNIque Physical Activity Intervention for Rheumatoid Arthritis During the COVID19 Pandemic

    Dana Guglielmo, San Diego, CA

    Background/Purpose: I was diagnosed with rheumatoid arthritis at age 17. In my 20s, I joined Racing For A Cure of the Arthritis National Research Foundation,…
  • Abstract Number: 1944 • ACR Convergence 2021

    Sustained Remission/Low Disease Activity Is Feasible in the Long Term in Patients with Psoriatic Arthritis Treated with IL-23/12 Inhibition with Ustekinumab (STELARA®) and Tumor Necrosis Factor Inhibitors in a Real-World, Multicenter Study

    Josef Smolen1, Paul Bergmans2, Kurt de Vlam3, Elisa Gremese4, Beatriz Joven-Ibáñez5, Tatiana Korotaeva6, Wim Noël7, Michael Nurmohamed8, Petros Sfikakis9, Stefan Siebert10, Elke Theander11 and Laure Gossec12, 1Medical University of Vienna, Vienna, Austria, 2Janssen-Cilag BV, Breda, Netherlands, 3University Hospitals Leuven, Leuven, Belgium, 4Fondazione Policlinico A Gemelli-IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, 5University Hospital 12 de Octubre, Madrid, Spain, 6VA Nasonova Research Institute of Rheumatology, Moscow, Russia, 7Janssen Pharmaceutica, HEMAR Department, Beerse, Belgium, 8Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, 9National Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, 10University of Glasgow, Glasgow, United Kingdom, 11Janssen Cilag, Lund, Sweden, 12Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France

    Background/Purpose: Among treatment options for PsA, IL-23/12 inhibition with ustekinumab (UST) was the first new biologic after TNF inhibitors (TNFi). Few data compare long-term effectiveness…
  • Abstract Number: 1926 • ACR Convergence 2021

    Effectiveness of the Making It Work™ Program at Improving Absenteeism in Workers with Inflammatory Arthritis – Results of a Randomized Controlled Trial

    Andre Luquini1, Yufei Zheng2, Hui Xie2, Catherine L. Backman3, Pamela Rogers4, Alex Kwok4, Astrid Knight4, Monique Gignac5, Dianne Mosher6, Linda Li3, John Esdaile7, Carter Thorne8 and Diane Lacaille2, 1University of British Columbia / Arthritis Research Canada, Fort Saint John, BC, Canada, 2Arthritis Research Canada, Richmond, BC, Canada, 3University of British Columbia, Vancouver, BC, Canada, 4Arthritis Research Canada / UBC, Vancouver, BC, Canada, 5Institute for Work & Health, Toronto, ON, Canada, 6University of Calgary, Calgary, AB, Canada, 7Arthritis Research Canada, Vancouver, BC, Canada, 8Southlake Regional Health Centre, Newmarket, ON, Canada

    Background/Purpose: Despite advances in treatment, absenteeism remains a major problem for workers living with inflammatory arthritis (IA), leading to reduced income and quality of life.…
  • Abstract Number: PP05 • ACR Convergence 2021

    Fighting Health-Related Misinformation Using Social Media / How Creating an Online Group for Patients with Relapsing Polychondritis — and Moderating It with Health Professionals — Helps Spread Reliable and Empowering Information

    Michael Linn1, Spenser Mestel2 and Susie Ratledge3, 1Relapsing Polychondritis Foundation, New York, NY, 2New York, NY, 3Relapsing Polychondritis: Secular Science and Support group, Chattanooga, TN

    Background/Purpose: Before I became ill in 2017, I was a registered nurse with a degree in health science who'd often educate patients about how they…
  • Abstract Number: PP09 • ACR Convergence 2021

    Family Planning while Living with Rheumatoid Arthritis

    Shannan O'Hara-Levi, Monroe, NY

    Background/Purpose: Over the course of my 30+ years living with Polyarticular Juvenile Rheumatoid Arthritis, I have never had long term success on any one biologic treatment,…
  • Abstract Number: PP07 • ACR Convergence 2021

    How Online Spanish-Language Resources Got Me and My RA Through the COVID-19 Pandemic

    Wigna Cruz, Puerto Rico

    Background/Purpose: I was experiencing joint pain especially in my wrists, which led me to see my physician for testing. Initially I was misdiagnosed with lupus.…
  • Abstract Number: PP12 • ACR Convergence 2021

    Fighting for the Care We Deserve: My Experience as a Latina Patient-Researcher During the COVID-19 Pandemic

    Guadalupe Torres1, Courtney Wells2 and Kristine Carandang3, 1, 2University of Wisconsin-River Falls, School of Social Work, St. Paul, MN, 3Global Healthy Living Foundation, CreakyJoints, San Diego, CA

    Background/Purpose: I am a 23-year-old first generation Latina with rheumatoid arthritis (RA). Despite being disproportionately affected by rheumatic conditions, the perspectives of Latinx remain poorly…
  • Abstract Number: PP11 • ACR Convergence 2021

    “Our Arthritis May Be Chronic but We Are Definitely Iconic” – Two Teens Created a National Podcast for Youth with Rheumatic Diseases

    Trishtha Peters1 and Natasha Trehan2, 1University of Ontario, Toronto, ON, Canada, 2University of Ottawa, Toronto, ON, Canada

    Background/Purpose: Trish Peters was diagnosed with JIA at 11. She has been on Methotrexate to lessen disease activity for her knees and hands. She does…
  • Abstract Number: PP13 • ACR Convergence 2021

    CreakyKitchen: How the Online Cooking Show I Started is Building Community and Encouraging Better Food Choices for Me and Others Living with Rheumatic and Chronic Disease

    Chantelle Marcial, Boston, MA

    Background/Purpose: At 19, I was mis-diagnosed with Lupus as it was a common condition in my family. My treatment at that time was mainly DMARDs,…
  • Abstract Number: PP03 • ACR Convergence 2021

    Navigating Maintenance of a Rare Autoimmune Rheumatic Disease in the Context of the COVID-19 Pandemic

    Ida Hakkarinen, Greenbelt, MD

    Background/Purpose: On March 13th, 2020, the President of the United States issued a proclamation declaring that the outbreak of coronavirus disease 2019 (COVID-19) was a…
  • Abstract Number: 1925 • ACR Convergence 2021

    Risk of Heart Failure in Patients with Inflammatory Disease: A Population-Based Study

    Sahil Koppikar1, Bindee Kuriya2, Jacob Udell3, Bing Yu4, Anna Chu4, Laura Ferreira-Legere5, Douglas Lee3, Jessica Widdifield6 and Lihi Eder3, 1Women's College Hospital, Toronto, ON, Canada, 2University of Toronto - Toronto, Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada, 4ICES, Toronto, ON, Canada, 5ICES, Toronto, Canada, 6Sunnybrook Research Institute; ICES; Institute of Health Policy, Management & Evaluation, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Individuals with inflammatory diseases (ID) have an increased risk of cardiovascular disease, frequently compared to that of diabetes mellitus (DM). However, the magnitude of…
  • Abstract Number: 1781 • ACR Convergence 2021

    A Direct-to-Patient PsA Screening Survey for Earlier Identification of At-Risk Psoriasis Patients and Reduction of Physician Burden

    Megan Meier1, Jessica Walsh2 and Shaobo Pei3, 1University of Utah, Salt Lake City, UT, 2Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, 3Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT

    Background/Purpose: Diagnostic delays are common with psoriatic arthritis (PsA) and contribute to unnecessary impairments in quality of life and function. Screening surveys for identifying at-risk…
  • « Previous Page
  • 1
  • …
  • 638
  • 639
  • 640
  • 641
  • 642
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology